Navigation Links
Regulus Reports Second Quarter 2014 Financial Results and Recent Highlights
Date:8/6/2014

esearch with Biogen Idec; Regulus to Receive $2M Upfront Payment.  Regulus entered into a new collaboration agreement with Biogen Idec to expand its research focused on identifying microRNAs as biomarkers for multiple sclerosis ("MS") under its Regulus microMarkers™ division.  The new research will focus on profiling a large number of whole blood samples from a cohort of MS patients who have been treated with a Biogen Idec MS therapy to identify potential microRNA signatures.  Regulus will receive $2.0 million upfront and is eligible for future payments upon achievement of certain milestones related to the identification of potential microRNA signatures.  Regulus and Biogen Idec began their collaboration in August 2012 to identify potential microRNA biomarkers in MS.  The results of this previous work helped define the scope of the research under the new collaboration agreement, which resulted in a termination of the August 2012 agreement.
  • Orphan Designation Granted to RG-012 from the U.S. Food and Drug Administration. Recently, the U.S. Food & Drug Administration granted orphan drug designation to RG-012, an anti-miR targeting microRNA-21 ("miR-21"), as a therapeutic for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.  In the near term, Regulus expects to initiate a natural history of disease study to gather greater information about the progression of Alport syndrome and to inform future clinical development plans of RG-012.
    Under the 'Clinical Map Initiative', Regulus expects to initiate a Phase I clinical study of RG-012 in the first half of 2015.
  • Second Quarter 2014 Highlights

  • Phase I Clinical Study of RG-101 for the Treatment of HCV Ongoing. Regulus is evaluating RG-101, a GalNAc-conjugated anti-miR that targets microRNA-122 ("miR-122"), in a Phase I clinical study for the treatment of chronic hepatitis C virus infection ("HCV").  Th
    '/>"/>

  • SOURCE Regulus Therapeutics Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis
    2. Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome
    3. Regulus Announces Addition to NASDAQ Biotechnology Index
    4. Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
    5. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
    6. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
    7. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
    8. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
    9. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
    10. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
    11. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/22/2015)... 22, 2015  The U.S. Food and Drug ... the first biosimilar product approved in ... growth in the contract manufacturing organization (CMO) industry, ... is geared to the production of small-molecular drugs ... products. The healthcare market research publisher,s report, ...
    (Date:5/22/2015)... 20, 2015 Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ... "Guide to Prepare Application Dossiers for Oversea Medical ... " report to their offering. ... segment market of the most growth potentiality, which ... manufacturers and producers to penetrate such market. It ...
    (Date:5/22/2015)... 22, 2015 Richmond Pharmacology ... unit with a worldwide reputation for excellence in ... publications in peer reviewed medical journals. Its officers ... regulators in discussions about rules for transparency and ... (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research is ...
    Breaking Medicine Technology:Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3
    ... - Arrowhead,Research Corporation (NASDAQ:ARWR) announced today that,majority-owned ... Proceedings of the National Academy of Sciences,(PNAS) ... use multiple,systemic dosing with Calando's lead siRNA ... technologies in targeted,polymeric delivery systems and siRNA ...
    ... in Two Most Common Mutations, CRANBURY, N.J., ... biopharmaceutical company developing small,molecule, orally-administered pharmacological chaperones ... genetic diseases, announced today,that it will present ... tartrate, AT2101) for Gaucher disease at,the of ...
    Cached Medicine Technology:Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 2Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 3Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3
    (Date:5/22/2015)... 2015 Mountain Point Medical Center, a campus ... ceremony on Friday, May 29, 2015 at 11 a.m., followed ... The new medical center, set to officially open on June ... UT 84043. , “The opening of Mountain Point Medical ... Utah County community,” said Kent Loosle, CEO of Mountain Point ...
    (Date:5/22/2015)... 2015 Combination therapy, or polytherapy, ... chronic obstructive pulmonary disorder (COPD) as the dominant ... plc as well as Germany’s Boehringer Ingelheim compete ... But will market payers, clinicians and patients be ... to completely new ones? , In spite of ...
    (Date:5/22/2015)... Coordinating care for people with ... providers have not been reimbursed or rewarded for ... Medicare has paved the way by offering reimbursement ... launch of Oculus Health , an innovative ... the platform will now be able to easily ...
    (Date:5/22/2015)... (PRWEB) May 22, 2015 ... Health IT solutions, announced today that Bill Lane, ... is the developer of BlueEHS,a first of its ... offers a customizable Electronic Health Records (EHR) with ... interfaces, a telemedicine-enabled comprehensive patient portal, and more. ...
    (Date:5/22/2015)... (PRWEB) May 22, 2015 sweetFrog Enterprises, LLC. ... in Jacksonville, Texas. Jacksonville is now the 16th sweetFrog store ... chain was listed as #22 on the Inc. 500 list ... have lived and worked in East Texas for 20 years ... Anderson, owner of the Jacksonville, and nearby Palestine, sweetFrog locations. ...
    Breaking Medicine News(10 mins):Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2
    ... prevention or delay of full-blown disease seen in treated ... Among patients who show early signs of multiple sclerosis, ... halve the risk that they will develop full-blown disease, ... who are diagnosed with multiple sclerosis first show signs ...
    ... With the thermometer dropping and the onset of flu ... and the public to encourage them to get a seasonal ... supported healthy behaviors and prevention efforts," said Merri Dee, AARP ... protect themselves and those around them by getting vaccinated." , ...
    ... $30 billion and $34 billion reside in the asbestos ... to pay claims brought by workers who contracted asbestos-related ... Asbestos Litigation Conference" produced in San Francisco by HB ... state court judges from around the country who shared ...
    ... WASHINGTON, Pa., Oct. 6 RAM Technologies, Inc., ... for health plans, has once again been named ... Tech Employers in the Greater Philadelphia region. ... edge applications that automate the administration of health ...
    ... While little is known about the causes of glioma, ... this rare but often deadly form of brain cancer ... height. "Our findings suggest that biological factors ... play a role in glioma etiology. This clue could ...
    ... ... 2009 News Briefs are designed to keep you up-to-date on embargoed studies ... Society of Plastic Surgeons (ASPS) held October 23-27 in Seattle. All briefs ... advance copy of study abstracts, for media registration, or to arrange interviews ...
    Cached Medicine News:Health News:Early Drug Treatment May Cut Multiple Sclerosis Risk 2Health News:AARP Encourages All Adults 50+ to Get Flu Vaccine This Season 2Health News:Asbestos Trusts, Asbestos Judges Featured at Two HB Events Dec. 2 & 3 2Health News:RAM Technologies Named to Philadelphia Business Journal's List of Top Tech Employers 2Health News:Physical activity in adolescence associated with decreased risk of brain cancer in adulthood 2Health News:Physical activity in adolescence associated with decreased risk of brain cancer in adulthood 3Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 2Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 3Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 4Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 5Health News:Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25 6
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: